Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Bleeding Disorders Treatment Market Through 2034?

The market size for treating bleeding disorders has seen significant growth recently. The size is projected to expand from $16.95 billion in 2024 to $18.45 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. The growth observed in the historical period is attributable to an increase in patient consciousness, improved healthcare accessibility, breakthroughs in haemophilia treatments, and the global market’s expansion.

Anticipated to experience significant expansion in the upcoming years, the market size of bleeding disorders treatment is likely to reach an estimated worth of$25.93 billion” by 2029, exhibiting a compound annual growth rate (CAGR) of 8.9%. The propelling factors for this predicted growth during the forecast period include the aging population, customized medical treatments, advocacy and support for patients, increased disposable incomes, and a surging expenditure on healthcare. Key trends foreseen in the forecasted era include the adaptation of personalized treatment regimes, amplified utilization of telehealth services, advancement in clotting factor therapies, RNA-based treatments, and availability of orphan drug designation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7843&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Bleeding Disorders Treatment Market?

The bleeding disorders treatment market is anticipated to grow with the rise in diagnosed hemophilia cases. Hemophilia, an inherited disorder affecting the blood’s capability to clot, is primarily treated via replacement therapy. This therapy replaces insufficient or missing blood clotting factors with either human plasma concentrates or recombinant forms of clotting factors VIII or IX. The World Federation of Hemophilia (WFH), a not-for-profit organization out of Canada, reported in 2022 that the number of identified hemophilia patients globally stood at 257,146, which includes 208,957 Hemophilia A and 42,203 Hemophilia B patients. Hence, this uptick in diagnosed hemophilia patients is contributing to the growth of the bleeding disorders treatment market.

Which Key Market Segments Comprise the Bleeding Disorders Treatment Market and Drive Its Revenue Growth?

The bleeding disorders treatmentmarket covered in this report is segmented –

1) By Treatment: Desmopressin (DDAVP); Hormone Replacement Therapy; Contraceptives; Anti-Fibrinolytic or Clot-Stabilizing Drugs; Fibrin Sealants; Drugs Applied To Cuts; Pipeline Analysis

2) By Disease Type: Hemophilia A; Hemophilia B; Von Willebrand disease; Liver disease; Other Disease Types

3) By End User: Hospitals; Clinics; Specialty Clinics; Research Institutes; Other End Users

Subsegments:

1) By Desmopressin (DDAVP): Intravenous Formulations; Nasal Spray Formulations

2) By Hormone Replacement Therapy: Estrogen Therapy; Progesterone Therapy

3) By Contraceptives: Combined Oral Contraceptives; Progestin-Only Contraceptives

4) By Anti-Fibrinolytic or Clot-Stabilizing Drugs: Tranexamic Acid; Aminocaproic Acid

5) By Fibrin Sealants: Tisseel; Artiss

6) By Drugs Applied To Cuts: Antiseptics; Topical Hemostatic Agents

7) By Pipeline Analysis: Upcoming Treatments in Development; Novel Therapeutics and Technologies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7843&type=smp

Which Areas Are Leading Regions in the Bleeding Disorders Treatment Market Expansion Across the Globe?

North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Strategic Trends Steering theBleeding Disorders Treatment Market Direction?

Major players in the bleeding disorder treatment market are concentrating their efforts towards the maturation of novel technologies like single-dose treatments. These innovative methods aim to augment the efficacy of treatments and improve the lifestyle of patients by eliminating the requirement for continuous therapy routines. A single-dose treatment proposes a method where the entire therapy is delivered in one go, with the goal of achieving enduring outcomes without the multiple dosage necessity. For instance, in June 2023, BioMarin Pharmaceutical Inc., a biotech firm in the US, introduced BioMarin’s ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN is specifically earmarked for adults severely suffering from hemophilia A (characterized as FVIII activity levels below 1 IU/dL) who, as verified by an FDA-sanctioned test, do not possess pre-existing antibodies to adeno-associated virus serotype 5 (AAV5).

View the full report here:

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

How Is the Bleeding Disorders Treatment Market Conceptually Defined?

Bleeding Disorders Treatment refers to medical therapies and interventions used to manage and control conditions that affect the blood’s ability to clot properly. These treatments aim to prevent excessive bleeding, manage symptoms, and improve quality of life.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7843

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model